SEATTLE--(BUSINESS WIRE)--Adaptive Biotechnologies, the leader in combining next-generation sequencing and expert bioinformatics to profile T-cell and B-cell receptors of the adaptive immune system, and its collaborators from academic institutions around the world will share data further demonstrating the validity and prognostic value of the clonoSEQ® Process for minimal residual disease (MRD) assessment in lymphoid cancers in three oral and eight poster presentations, encompassing six different blood cancer subtypes, at the American Society of Hematology (ASH) Annual Meeting, December 5-8, 2015 in Orlando, FL.
Help employers find you! Check out all the jobs and post your resume.
